medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2021-3-14-22medalphabet-1926Research ArticleНЕВРОЛОГИЯ И ПСИХИАТРИЯNEUROLOGY AND PSYCHIATRYКлинические проявления, патогенез и лечение отдаленных последствий поражения нервной системы при COVID-19Clinical features, pathogenesis and treatment of long-haul COVID‑19 impact on nervous systemhttps://orcid.org/0000-0001-7146-2024БариновА. Н.BarinovA. N.

Баринов Алексей Николаевич, к.м.н., доцент кафедры нервных болезней и нейрохирургии

mmom-mc@mail.ruhttps://orcid.org/0000-0003-2076-4131МошхоеваЛ. С.MoshkhoevaL. S.

Мошхоева Люба Султановна, к.м.н., аспирант кафедры нервных болезней и нейрохирургии 

https://orcid.org/0000-0003-0489-9845ПархоменкоЕ. В.ParkhomenkoE. V.

Пархоменко Екатерина Васильевна, доцент кафедры неврологии и нейрохирургии с курсом ДПО 

https://orcid.org/0000-0003-1914-7566ЭмихЕ. В.EmikhE. V.

Эмих Елена Владимировна, ведущий невролог 

https://orcid.org/0000-0002-3429-9640ЯстребцеваИ. П.YastrebtsevaI. P.

Ястребцева Ирина Петровна, д.м.н., доцент, проф. кафедры неврологии и нейрохирургии ORCID

ip.2007@mail.ruФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (Сеченовский университет)РоссияFirst Moscow State Medical University n.a. I.M. SechenovRussian FederationФГБОУ ВО «Алтайский государственный медицинский университет» Минздрава РоссииРоссияAltai State Medical UniversityRussian FederationСеть клиник «Инвитро»РоссияInvitro’ Clinics’ NetworkRussian FederationФГБОУ ВО «Ивановская государственная медицинская академия» Минздрава РоссииРоссияIvanovo State Medical AcademyRussian Federation20212703202103Неврология и психиатрия (1)1422Copyright © Баринов А.Н., Мошхоева Л.С., Пархоменко Е.В., Эмих Е.В., Ястребцева И.П., 20212021Баринов А.Н., Мошхоева Л.С., Пархоменко Е.В., Эмих Е.В., Ястребцева И.П.Barinov A.N., Moshkhoeva L.S., Parkhomenko E.V., Emikh E.V., Yastrebtseva I.P.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/1926

Во всем мире усиленно изучается болезнь, вызываемая коронавирусной инфекцией SARS-CoV‑2 (COVID‑19), но ее воздействие на нервную систему требует дополнительных исследований. Симптомы COVID‑19 у 30 % больных продолжаются более 2 недель, необходимых для реконвалесценции, а у 10% пациентов – более 12 недель; это состояние получило название «длительный COVID». Оно развивается независимо от степени тяжести заболевания. Многие больные с длительным заболеванием продолжают испытывать те же симптомы, что имели в дебюте COVID‑19 – астению, когнитивные нарушения (мозговой туман), одышку, головную боль, депрессию, нарушение сна, потерю обоняния и (или) вкуса. Лечение этих осложнений цитиколином, этилметилгидроксипиридина сукцинатом и комплексами витаминов группы В улучшает симптомы, но большинство таких пациентов нуждаются в деипохондризации посредством когнитивной терапии.

The current outbreak of coronavirus SARS-CoV‑2 (COVID-19) has raised great concern worldwide, but its impact on nervous system still needs more investigation. Thirty per cent of symptomatic patients with COVID‑19 will have symptoms that last longer than the typical two weeks, 10 % have symptoms longer than 3 months and this is called ‘long-COVID’. These symptoms affect not only people with severe disease, but also those with milder cases. Many long-haulers experience the same symptoms they had during their initial fight with COVID‑19, such as fatigue, cognitive impairment (or brain fog), difficulty breathing, headache, depression, insomnia and loss of the sense of taste and\or smell. Treatment of those complications with citicoline, ethylmethylhydroxypyridine succinate and vitamin B improves these symptoms in patients but most of them also need cognitive therapy for dehypochondrisation.

SARS-CoV 2неврологические осложненияаносмияпаросмияфантосмияавтономная невропатиякогнитивные нарушениякогнитивная терапияцитиколинэтилметилгидроксипиридина сукцинатлечение витаминами группы ВSARS-CoV 2neurological complicationsanosmiaparosmiafantosmiaautonomic neuropathycognitive impairmentcognitive therapyciticolineethylmethylhydroxypyridine succinatevitamin B treatmentReferencesTemporary emergency guidance to US stroke centers during the coronavirus disease 2019 (COVID 19) pandemic: On Behalf of the American Heart Association / American Stroke Association Stroke Council Leadership. Stroke. 2020; 51 (6): 1910–1912. https://doi.org/10.1161/STROKEAHA.120.030023.Temporary emergency guidance to US stroke centers during the coronavirus disease 2019 (COVID 19) pandemic: On Behalf of the American Heart Association / American Stroke Association Stroke Council Leadership. Stroke. 2020; 51 (6): 1910–1912. https://doi.org/10.1161/STROKEAHA.120.030023.Song E., Zhang C., Israelow B. et al. Neuroinvasion of SARS-CoV 2 in human and mouse brain. Journal of Experimental Medicine. 2021; 218 (3): e20202135. https://doi: org/10.1084/jem.20202135.Song E., Zhang C., Israelow B. et al. Neuroinvasion of SARS-CoV 2 in human and mouse brain. Journal of Experimental Medicine. 2021; 218 (3): e20202135. https://doi: org/10.1084/jem.20202135.Miners S., Kehoe P.G., Love, S. Cognitive impact of COVID 19: looking beyond the short term. Alzheimers Res Therapy. 2020; 12 (1): 170. https://doi.org/10.1186/ s13195–020–00744-w.Miners S., Kehoe P.G., Love, S. Cognitive impact of COVID 19: looking beyond the short term. Alzheimers Res Therapy. 2020; 12 (1): 170. https://doi.org/10.1186/ s13195–020–00744-w.Ye M., Ren Y., Lv T. Encephalitis as a clinical manifestation of COVID 19. Brain, behavior, and immunity. 2020; (88): 945–946. https://doi.org/10.1016/j.bbi.2020.04.017.Ye M., Ren Y., Lv T. Encephalitis as a clinical manifestation of COVID 19. Brain, behavior, and immunity. 2020; (88): 945–946. https://doi.org/10.1016/j.bbi.2020.04.017.Huang Y.H., Jiang D., Huang J. T. SARS-CoV 2 Detected in Cerebrospinal Fluid by PCR in a Case of COVID 19. Encephalitis. Brain, behavior, and immunity. 2020; (87): 149. https://doi.org/10.1016/j.bbi.2020.05.012.Huang Y.H., Jiang D., Huang J. T. SARS-CoV 2 Detected in Cerebrospinal Fluid by PCR in a Case of COVID 19. Encephalitis. Brain, behavior, and immunity. 2020; (87): 149. https://doi.org/10.1016/j.bbi.2020.05.012.Wu Y., Xu X., Chen Z., et al. Nervous system involvement after infection with COVID 19 and other coronaviruses. Brain, behavior, and immunity. 2020; (87): 18–22. https://doi.org/10.1016/j.bbi.2020.03.031.Wu Y., Xu X., Chen Z., et al. Nervous system involvement after infection with COVID 19 and other coronaviruses. Brain, behavior, and immunity. 2020; (87): 18–22. https://doi.org/10.1016/j.bbi.2020.03.031.Karuppan M., Devadoss D., Nair M., et al. SARS-CoV 2 Infection in the Central and Peripheral Nervous System-Associated Morbidities and Their Potential Mechanism. Molecular neurobiology. 2021; 1–16. https://doi.org/10.1007/s12035–020–02245–1.Karuppan M., Devadoss D., Nair M., et al. SARS-CoV 2 Infection in the Central and Peripheral Nervous System-Associated Morbidities and Their Potential Mechanism. Molecular neurobiology. 2021; 1–16. https://doi.org/10.1007/s12035–020–02245–1.Esposito G., Pesce M., Seguella L., et al. Can the enteric nervous system be an alternative entrance door in SARS-CoV2 neuroinvasion? Brain, behavior, and immunity. 2020; (87): 93–94. https://doi. org/10.1016/j.bbi.2020.04.060.Esposito G., Pesce M., Seguella L., et al. Can the enteric nervous system be an alternative entrance door in SARS-CoV2 neuroinvasion? Brain, behavior, and immunity. 2020; (87): 93–94. https://doi. org/10.1016/j.bbi.2020.04.060.Wu Y., Xu X., Chen Z., et al. Nervous system involvement after infection with COVID 19 and other coronaviruses. Brain, behavior, and immunity. 2020; (87): 18–22. https://doi.org/10.1016/j.bbi.2020.03.031.Wu Y., Xu X., Chen Z., et al. Nervous system involvement after infection with COVID 19 and other coronaviruses. Brain, behavior, and immunity. 2020; (87): 18–22. https://doi.org/10.1016/j.bbi.2020.03.031.Hartung H.P., Aktas O. COVID 19 and management of neuroimmunological disorders. Nature reviews. Neurology. 2020; 16 (7): 347–348. https://doi.org/10.1038/ s41582–020–0368–9.Hartung H.P., Aktas O. COVID 19 and management of neuroimmunological disorders. Nature reviews. Neurology. 2020; 16 (7): 347–348. https://doi.org/10.1038/ s41582–020–0368–9.Mehta P., McAuley D.F., Brown M., et al. COVID 19: consider cytokine storm syndromes and immunosuppression. Lancet (London, England). 2020; 395 (10229): 1033–1034. https://doi.org/10.1016/S0140–6736(20)30628–0.Mehta P., McAuley D.F., Brown M., et al. COVID 19: consider cytokine storm syndromes and immunosuppression. Lancet (London, England). 2020; 395 (10229): 1033–1034. https://doi.org/10.1016/S0140–6736(20)30628–0.Karuppan M., Devadoss D., Nair M., et al. SARS-CoV 2 Infection in the Central and Peripheral Nervous System-Associated Morbidities and Their Potential Mechanism. Molecular neurobiology. 2021; 1–16. Advance online publication. https://doi.org/10.1007/s12035–020–02245–1.Karuppan M., Devadoss D., Nair M., et al. SARS-CoV 2 Infection in the Central and Peripheral Nervous System-Associated Morbidities and Their Potential Mechanism. Molecular neurobiology. 2021; 1–16. Advance online publication. https://doi.org/10.1007/s12035–020–02245–1.Torabi A., Mohammadbagheri E., Akbari Dilmaghani N., et al. Proinflammatory Cytokines in the Olfactory Mucosa Result in COVID 19 Induced Anosmia. ACS chemical neuroscience. 2020; 11 (13): 1909–1913. https://doi.org/10.1021/ acschemneuro.0c00249.Torabi A., Mohammadbagheri E., Akbari Dilmaghani N., et al. Proinflammatory Cytokines in the Olfactory Mucosa Result in COVID 19 Induced Anosmia. ACS chemical neuroscience. 2020; 11 (13): 1909–1913. https://doi.org/10.1021/ acschemneuro.0c00249.Lechien J.R., Chiesa-Estomba C. M., Beckers E., et al. Prevalence and 6-month recovery of olfactory dysfunction: a multicentre study of 1363 COVID-19 patients. J Intern Med. 2021; https://doi.org/10.1111/joim.13209 https://onlinelibrary.wiley. com/doi/10.1111/joim.13209.Lechien J.R., Chiesa-Estomba C. M., Beckers E., et al. Prevalence and 6-month recovery of olfactory dysfunction: a multicentre study of 1363 COVID-19 patients. J Intern Med. 2021; https://doi.org/10.1111/joim.13209 https://onlinelibrary.wiley. com/doi/10.1111/joim.13209.Gareri P., Castagna A., Cotroneo A.M., et al. The role of citicoline in cognitive impairment: pharmacological characteristics, possible advantages, and doubts for an old drug with new perspectives. Clinical interventions in aging. 2015; (10): 1421–1429. https://doi.org/10.2147/CIA.S87886.Gareri P., Castagna A., Cotroneo A.M., et al. The role of citicoline in cognitive impairment: pharmacological characteristics, possible advantages, and doubts for an old drug with new perspectives. Clinical interventions in aging. 2015; (10): 1421–1429. https://doi.org/10.2147/CIA.S87886.Steardo L., Steardo L., Jr Zorec, R. Verkhratsky A. Neuroinfection may contribute to pathophysiology and clinical manifestations of COVID 19. Acta physiologica. 2020; 229 (3): e13473. https://doi.org/10.1111/apha.13473.Steardo L., Steardo L., Jr Zorec, R. Verkhratsky A. Neuroinfection may contribute to pathophysiology and clinical manifestations of COVID 19. Acta physiologica. 2020; 229 (3): e13473. https://doi.org/10.1111/apha.13473.Li Y., Li H., Fan R., et al. Coronavirus Infections in the Central Nervous System and Respiratory Tract Show Distinct Features in Hospitalized Children. Intervirology. 2016; 59 (3): 163–169. https://doi.org/10.1159/000453066.Li Y., Li H., Fan R., et al. Coronavirus Infections in the Central Nervous System and Respiratory Tract Show Distinct Features in Hospitalized Children. Intervirology. 2016; 59 (3): 163–169. https://doi.org/10.1159/000453066.Mehta P., McAuley D.F., Brown M., et al. COVID 19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020; 395 (10229): 1033–1034. https://doi.org/10.1016/S0140–6736(20)30628–0.Mehta P., McAuley D.F., Brown M., et al. COVID 19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020; 395 (10229): 1033–1034. https://doi.org/10.1016/S0140–6736(20)30628–0.Mahmudpour M., Roozbeh J., Keshavarz M., et al. COVID 19 cytokine storm: The anger of inflammation. Cytokine. 2020; 133: 155151. https://doi.org/10.1016/j. cyto.2020.155151.Mahmudpour M., Roozbeh J., Keshavarz M., et al. COVID 19 cytokine storm: The anger of inflammation. Cytokine. 2020; 133: 155151. https://doi.org/10.1016/j. cyto.2020.155151.Zheng Z., Peng F., Xu B., et al. Risk factors of critical & mortal COVID 19 cases: A systematic literature review and meta-analysis. The Journal of infection. 2020; 81 (2): e16–e25. https://doi.org/10.1016/j.jinf.2020.04.021.Zheng Z., Peng F., Xu B., et al. Risk factors of critical & mortal COVID 19 cases: A systematic literature review and meta-analysis. The Journal of infection. 2020; 81 (2): e16–e25. https://doi.org/10.1016/j.jinf.2020.04.021.Строков И.А., Баринов А.Н., Новосадова М.В., Яхно Н.Н. Клинические методы оценки тяжести диабетической полиневропатии. Неврологический журнал. 2000; (5) № 5: 14–19.Strokov I.A., Barinov A.N., Novosadova M.V., Yakhno N.N. Clinical scales for grading the severity of diabetic neuropathy. Nevrologichesky journal. 2000; (5) N5: 14–19.Freeman R., Low P., Tesfaye S., Valensi P. Toronto Consensus Panel on Diabetic Neuropathy. Methods of investigation for cardiac autonomic dysfunction in human research studies. Diabetes Metab Res Rev. 2011; 27 (7): 654–64. https://doi. org/10.1002/dmrr.1224. PMID: 21695761.Freeman R., Low P., Tesfaye S., Valensi P. Toronto Consensus Panel on Diabetic Neuropathy. Methods of investigation for cardiac autonomic dysfunction in human research studies. Diabetes Metab Res Rev. 2011; 27 (7): 654–64. https://doi. org/10.1002/dmrr.1224. PMID: 21695761.Ewing D. J., Clarke B. F. Diagnosis and management of diabetic autonomic neuropathy. British medical journal (Clinical research ed.). 1982; 285 (6346): 916–918. https://doi.org/10.1136/bmj.285.6346.916.Ewing D. J., Clarke B. F. Diagnosis and management of diabetic autonomic neuropathy. British medical journal (Clinical research ed.). 1982; 285 (6346): 916–918. https://doi.org/10.1136/bmj.285.6346.916.Мошхоева Л.С., Баринов А.Н. Клинические проявления и диагностика автономной невропатии при сахарном диабете 2 типа и метаболическом синдроме. Opinion Leader 2020; № 12 (41): 90–97.Moshkhoeva L.S., Barinov A.N. Clinical features and diagnostics of autonomic neuropathy in patients with diabetes mellitus 2 and metabolic syndrome. Opinion Leader 2020; N12 (41): 90–97.Ахмеджанова Л. Т., Баринов А.Н., Строков И. А. Диабетические и недиабетические полиневропатии у пациентов с сахарным диабетом. Журнал неврологии и психиатрии. 2018; № 4 (118): 113–121.Akhmedzhanova L.T., Barinov A.N., Strokov I.A. Diabetic and other neuropathies in patients with diabetes mellitus. Journal nevrologii Ipsikhiatrii. 2018; N4 (118): 113–121.Баринов А.Н. Вегетативная невропатия при сахарном диабете и метаболическом синдроме: клинические проявления, диагностика и лечение. Эффективная фармакотерапия. 2017; № 2 (Эндокринология): 26–34.Barinov A.N. Autonomic neuropathy in patients with diabetes mellitus and metabolic syndrome. Effectivnaya farmakotherapia, 2017; N2 (Endocrinology): 26–34

The authors declare that there are no conflicts of interest present.